1165910-22-4

LGD-4033 is a Selective Androgen Receptor Modulator (SARM). SARMs are a class of non-steroidal anabolic agents that bind androgen receptors with high affinity. LGD-4033 has been shown to provide benefits similar to traditional anabolic agents, (e.g., increased muscle mass, fat loss, and improved bone density) but with far fewer side effects (e.g., oily skin, acne, over-conversion to estrogen, etc.). Both men and women may also appreciate improved libido. All of these benefits are achieved without increasing androgen levels. Its anabolic effects are roughly the same or greater than testosterone, even at low doses. Some prescribers will recommend a trial of SARMs for low testosterone levels prior to utilizing testosterone replacement therapy.

LGD-4033 is a nonsteroidal oral, selective androgen receptor modulator, in healthy young men.

LGD-4033 is a potent nonsteroidal selective androgen receptor modulator (SARM) that binds to the androgen receptor with a Ki value of 1 nM. In animal models, LGD-4033 displays robust selectivity for muscle versus prostate tissues, anabolic activity in the muscle, and anti-resorptive and anabolic activity in bone.
LGD 4033 has been abused as a performance-enhancing drug and the identification of its in vitro metabolites has been described.
This product is intended for research and forensic applications.

LGD-4033 works by binding to androgen receptors in muscle and bone tissue and stimulating protein synthesis, thus helping to build muscle and strength, increase bone density, reduce inflammation, and promote tissue healing. In addition, it can also help improve body composition by reducing fat mass while preserving lean muscle mass.

LGD-4033 functions by enlarging the androgen receptors, selectively. Anabolic effects on muscles and bones occur rather than negatively altering the prostate or glands, which could be caused through the use of steroids. LGD-4033 has recently been engaged in a study with volunteers called Phase 1 Multiple Ascending Dose. It was random,double blind testing phase in which placebo was used.The aim was to verify that the usage of LGD-4033 is safe and easy to use with a dosage not exceeding 22 mg daily.

When taken in appropriate doses, most people experience minimal side effects, if any at all. Some users may experience mild headaches, nausea, or lightheadedness, but these are generally mild and go away quickly.

LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

11.20 g Aldehyde (4-(2-(formylpyrrolidin-1-yl)-2-(trifluoromethyl)benzonitril )was dissolved in 300 ml dry tetrahydrofuran and 8.36 g CsF was added directly as a solid to the reaction mixture. It was cooled via ice bath to 0°C and stirred for 15 min. Then 25.00 g trimethyl(trifluoromethyl)silane was added via syringe over a period of 40 min. The reaction is stirred for 15 h coming from 0°C to room temperature over this time interval. The reaction solution shifts color from nearly colorless to dark brown. For stopping the reaction, it was diluted with 100 ml saturated ammonium chloride solution and then evaporated. The resulting emulsion was extracted several times with ethyl acetate and the combined phases dried over magnesium sulfate. After evaporation of all volatiles, the intermediate silyl-ether can be obtained as red-brown oil. This intermediate was converted to the final product LGD-4033 without any further purification. The intermediate was diluted with 400 ml tetrahydrofuran and cooled to 0°C. A cooled potassium hydroxide solution (4.76 g in 400 ml water) was mixed with the diluted oil and stirred at 0°C for 2h. After quenching with 300 ml water, the organic solvent was removed via evaporation from the mixture. The remaining brown oil was extracted with dichloromethane and dried over magnesium sulfate, to yield a reddish-brown oil. This crude product was chromatographed on silica gel by using hexane-ethyl acetat (8:2) as an eluent. During purification, different fractions with several product isomers can be collected . The isolated products LGD-4033 were obtained as 8.50 g yellowish oils (61%).

The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men
In vitro metabolism study of a black market product containing SARM LGD-4033
Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing